{"symbol":"BMY","fiscalQuarter":"Q2-2022","reportDate":"2022-07-27","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q2-2022","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Up 1.6%","keyNumbers":[{"metric":"EPS","actual":"$1.93","expected":"N/A","surprise":"+7.82%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management expressed satisfaction with the EPS performance despite not providing revenue figures.","They highlighted ongoing efforts in research and development as a priority for future growth."],"summary":"Overall, management conveyed a sense of cautious optimism regarding the company's financial health. They emphasized the importance of their ongoing projects and pipeline."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report shows a positive surprise in EPS, which contributed to a 1.6% increase in stock price. The lack of revenue data leaves some uncertainty, but management's focus on R&D suggests they are positioning for future growth. Investors may view the EPS beat as a sign of resilience in the company's financial performance.","metaDescription":"Bristol Myers Squibb (BMY) Q2 2022 earnings: EPS beat by 7.82%. Stock up 1.6%. Full breakdown."}}